#USA #Radiotherapy #Stratford #KUBTEC #XCELL TomoRad

KUBTEC® Scientific Brings a New Era to Radiotherapy

KUBTEC® Scientific, a frontrunner in X-ray imaging and irradiation technology, has proudly announced the launch of its latest innovation: the XCELL® TomoRad™ system, a cutting-edge solution in the field of image-guided radiotherapy (IGRT). This groundbreaking product is set to transform preclinical research by streamlining processes and making advanced radiotherapy techniques more accessible to laboratories worldwide.

Introducing the XCELL® TomoRad™ System

The XCELL® TomoRad™ integrates a sophisticated 3D imaging technique known as tomosynthesis, which collects multiple radiographic images from various angles to reconstruct a comprehensive three-dimensional view of the target area. This advanced method offers significant advantages over traditional micro-CT imaging, including markedly lower radiation exposure for samples, quicker image acquisition and reconstruction times, and reduced costs compared to existing micro-CT technologies.

Prior to the introduction of TomoRad, IGRT-compatible systems were often prohibitively expensive and complicated to set up, creating barriers for many researchers seeking to enhance their work with radiotherapy techniques. Responding to the need for improved accessibility, KUBTEC’s scientific team has developed the TomoRad to facilitate greater research opportunities across various laboratories.

Revolutionary Ultra-Fast Dose Administration

A standout feature of the TomoRad system is its unique ultra-fast dose delivery method, pending patent, called Mag Mode™. This innovative technique positions the sample close to the X-ray tube to ensure that the highest dose is administered in the shortest amount of time. For busy research labs, Mag Mode does not only promise to expedite treatment timelines but also significantly reduces the duration of anesthesia required for animal subjects, thereby minimizing stress on the animals involved in studies.

Vikram Butani, CEO of KUBTEC Scientific, expressed the vision behind the XCELL TomoRad at its unveiling, stating, “The entry barrier for researchers into image-guided radiotherapy has been exceedingly high due to bottlenecks related to imaging and treatment speed, along with the complexity and cost of existing options. We have been made aware of the challenges involved in balancing precision targeting with efficiency and workflow simplicity. KUBTEC has always aimed to develop preclinical technologies that enable researchers to study and refine their work into better clinical care. We believe that the XCELL TomoRad will continue this journey by reducing radiation dose and accelerating treatment cycles for patients.”

A Commitment to Transformative Research Tools

With over 20 years at the forefront of X-ray imaging and irradiation technology, KUBTEC® Scientific has dedicated itself to advancing transformative solutions in preclinical applications. Their commitment to innovation is evident in the XCELL® TomoRad™ system, designed to provide researchers with the tools necessary to tackle some of the most challenging problems in the field. By making image-guided radiotherapy more affordable and user-friendly, KUBTEC firmly places itself as a champion for laboratory researchers worldwide.

For additional information regarding the XCELL® TomoRad™ image-guided radiotherapy system and its capabilities, please visit KUBTEC Scientific.

About KUBTEC® Scientific

KUBTEC® Scientific is passionate about developing transformative technologies for preclinical applications. Pioneering X-ray imaging and irradiation systems for more than two decades, they offer a comprehensive range of tools for disease study. Their innovative and proprietary technologies and software empower researchers to address the toughest challenges they encounter.